Background: Podocyte infolding glomerulopathy (PIG) is a peculiar and very rare manifestation in renal pathology. Its underlying pathogenesis mechanism and clinical characteristics remain unclear due to sparse reports. Objective: To further elucidate the clinical profile of PIG by carefully reporting our four cases and a comprehensive review of cases in the literature. Methods: This study retrospectively reviewed four cases of PIG from 2010 to 2022 in our centre. Clinical and pathological profiles were reported. PIG cases in the literature were searched in the MEDLINE database and analysed together with our cases. Results: Four cases of PIG identified from our centre and 40 cases from the current literature were reported. The pooled analysis of these 44 cases indicated 79.5% (35/44) were females, 93.2% (41/44) were East Asians, and 63.6% (28/44) were reported in Japan. The average age was 42.0 ± 12.5 years old. The average amount of proteinuria at the time of renal biopsy was 3.06 ± 3.2 g/day. The most reported comorbidities were connective tissue diseases, mainly systemic lupus erythematosus, and 20.5% (9/44) of the cases did not have any contaminant disease. Most of the cases (81.8%, 36/44) had been treated with immunosuppressants, of which a combination of corticosteroids and one other type of immunosuppressant was most commonly reported. In addition, 45.4% (20/44) and 34.1% (15/44) of the cases had achieved complete response and partial response, respectively, after treatment. Whole exosome sequencing indicated mutations in the INF2 gene. Conclusions: PIG is a rare condition and seen in relatively younger populations, often associated with connective tissue diseases clinically and one or two other glomerulopathies histologically. The outcomes following immunosuppressive treatment are relatively good. Mutations in INF2 might be involved in the development of PIG; however, the implications of these results need to be investigated.
Several genome-wide association studies revealed that several variants of UMOD gene were related to the estimated glomerular filtration rate (eGFR), CKD or hypertension. In this study, we investigated the association between a common variant rs13333226 in the promoter region of UMOD gene and end stage renal disease (ESRD). Variant rs13333226 of UMOD gene was genotyped by using the ABI Real time TaqMan allelic discrimination assay in a case-control study including 638 unrelated patients with ESRD and 366 controls. The frequency of UMOD SNP rs13333226 GG/GA genotype was significantly higher (36.83% vs. 20.22%, P = 4.02 × 10-8) and the frequency of G allele was much higher (19.04% vs. 11.20%, P = 4.00 × 10−6) in the patients with ESRD than in the controls. The G allele was associated with an increased risk of ESRD (odds ratio 2.30, 95% confidence interval 1.70–3.11, P = 6.10 × 10−8). And G allele (odds ratio 2.33, 95% confidence interval 1.32–4.13, P = 3.65 × 10−3) was associated independently with ESRD. A common variation rs13333226 in the promoter region of UMOD gene was independently associated with ESRD in Han Chinese.
Background: Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, being driven by incompletely understood autoimmune mechanisms. Emerging evidence suggests that γ-aminobutyric acid (GABA), traditionally considered a neurotransmitter, also functions as a critical immunomodulator in peripheral tissues. Dysregulation of GABAergic signaling has been linked to altered immune cell trafficking and metabolic stress in renal pathologies. However, its specific role and signature genes in MN pathogenesis have not been systematically characterized. This study aimed to identify novel GABA-associated biomarkers for MN and elucidate their potential mechanistic roles. Results: By integrating differential expression analysis, weighted gene coexpression network analysis, and machine learning algorithms on public transcriptomic datasets, we identified three robust GABA-associated candidate biomarkers: AP2S1 , STXBP1 , and GNGT2 . These genes were consistently upregulated in patients with MN across both the training and validation cohorts. Functional enrichment analysis revealed their significant involvement in vesicle trafficking, cytochrome P450 metabolism, and cell adhesion pathways. Immune infiltration analysis demonstrated that these biomarkers had strong positive correlations with central memory CD4 + T cells and myeloid-derived suppressor cells. Furthermore, molecular docking simulations indicated high binding affinities between these targets and potential therapeutic compounds, including valproic acid and genistein. Crucially, reverse transcription quantitative polymerase chain reaction validation in an independent clinical cohort ( n = 10) confirmed significantly elevated expression of AP2S1 , STXBP1 , and GNGT2 in the peripheral blood of patients with MN versus healthy controls ( P < 0.05). Conclusion: This study established a distinct GABAergic signature in MN, highlighting AP2S1 , STXBP1 , and GNGT2 as promising noninvasive diagnostic biomarkers. Our findings suggested that GABA-related vesicle trafficking and metabolic pathways contribute to the autoimmune microenvironment in MN. These genes offer new avenues for early diagnosis and represent potential therapeutic targets for precision medicine strategies in managing MN.